+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID05719441

Randomized Study of Combination Broadly Neutralizing Antibodies Plus ART Versus Placebo Plus ART During Acute HIV Infection to Study HIV Remission

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-10-14

48

Participants Needed

12

Research Sites

48 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults recently diagnosed with acute HIV infection to evaluate whether adding combination HIV-specific broadly neutralizing antibody bNAb therapy to standard antiretroviral therapy ART is safe and effective. This phase II randomized, double-blind, placebo-controlled study aims to see if this combination delays the return of detectable HIV levels during a supervised treatment pause and reduces viral reservoirs while enhancing HIV-specific immune responses. Participants will be randomly assigned to one of two groups one receiving combination bNAb therapy VRC07-523LS and PGT121.414.LS plus ART, and the other receiving placebo plus ART. The bNAbs are given as intravenous infusions once at the start, alongside daily oral ART medication. After initial treatment, participants will undergo a carefully monitored analytical treatment interruption ATI where ART is paused under supervision to assess HIV viral rebound. Throughout the study, participants will have regular monitoring including laboratory assessments of HIV viral load and immune cell counts, safety evaluations for adverse effects related to the study antibodies, and measurement of antibody levels in the body. The primary outcomes focus on safety and the time until HIV viral load rebounds to defined thresholds during ATI. The study duration includes up to 60 weeks of initial ART treatment and 24 weeks of follow-up during ATI to observe viral control and immune response.

CONDITIONS

Brief Title

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here